|
Oct 9
|
Zai Lab to Present Data from Phase 1 Trial of ZL-1310, Its Investigational Antibody-Drug Conjugate (ADC) for DLL3+ Solid Tumors, at EORTC-NCI-AACR Symposium (ENA) 2024
|
|
Jul 17
|
China NMPA approves Zai Lab-argenx’s efgartigimod alfa for gMG
|
|
Jul 16
|
Zai Lab and argenx Announce Approval of Efgartigimod Alfa Injection (Subcutaneous Injection) for Generalized Myasthenia Gravis in China
|
|
Jul 15
|
Zai Lab-Supported Study Published in Cell Provides New Insights with Potential to Improve Treatment of HRD-Positive Ovarian Cancers, Including Through Combination PARP Inhibitor and CCR8 Therapy
|
|
Jun 13
|
Increases to CEO Compensation Might Be Put On Hold For Now at Zai Lab Limited (NASDAQ:ZLAB)
|
|
Apr 11
|
Zai Lab Statement on Executive Management Team’s Agreement on Share Activities
|
|
Feb 29
|
Zai Lab Limited (NASDAQ:ZLAB) Q4 2023 Earnings Call Transcript
|
|
Feb 27
|
Zai Lab Ltd (ZLAB) Reports 25% Year-Over-Year Revenue Growth in Full-Year 2023 Financial Results
|
|
Feb 27
|
Zai Lab Announces Full-Year 2023 Financial Results and Recent Corporate Updates
|
|
Jan 10
|
Zai Lab Announces The New England Journal of Medicine Publication Demonstrating Durable Clinical Activity of Repotrectinib in Patients with Advanced ROS1 Fusion-Positive NSCLC
|
|
Jan 5
|
Zai Lab Ltd Chairperson & CEO Ying Du Sells 8,380 Shares
|
|
Dec 22
|
What Makes Zai Lab Limited Unsponsored ADR (ZLAB) a New Buy Stock
|
|
Dec 19
|
Zai Lab Announces Participation in January Investor Conference
|
|
Dec 13
|
Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List
|
|
Dec 13
|
Zai Lab Announces the First Listing of VYVGART® (efgartigimod alfa injection) and Other Updates in China’s National Reimbursement Drug List
|
|
Dec 7
|
Companies Like Zai Lab (NASDAQ:ZLAB) Are In A Position To Invest In Growth
|
|
Aug 10
|
Penn downgraded, Roblox upgraded: Wall Street's top analyst calls
|
|
Aug 7
|
Zai Lab Announces Second Quarter 2023 Financial Results and Corporate Updates
|